Literature DB >> 6159073

Cloning of human lymphocytes reactive with autologous leukemia cells.

G Csako, R A Binder, A N Kales, J R Neefe.   

Abstract

The primed lymphocyte typing test has been used to detect leukemia-associated antigens, but interpretation has been difficult because of significant levels of reactivity with normal cells. Elimination of unwanted reactivities could be accomplished by (a) use of the patient's own lymphocytes as responders to the leukemia cells and (b) cloning of the responding cells. Cloning of antigen-activated human lymphocytes can be accomplished through the use of T-lymphocyte growth factor, which permits the long-term growth of antigen-activated lymphocytes. In the study reported here, the remission lymphocytes of a patient with acute myelogenous leukemia were sensitized in culture to the patient's own leukemic myeloblasts and then grown from wells containing one or a few replicating units. Sufficient cells of three clones were growth for further testing of specificity: one responded only to the sensitizing myeloblast but not to normal cells tested; one responded to the sensitizing myeloblasts and one allogeneic myeloblast but not to normal cells; and one responded to none of the cells tested, although it proliferated vigorously with growth factor alone. These results demonstrate the feasibility of cloning human lymphocytes putatively responsive to leukemia-associated antigens in order to improve their discriminatory capacity in the primed lymphocyte typing test. The response pattern observed was that expected of a clone responding to a leukemia-associated antigen.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.

Authors:  G Pawelec; M Reutter; M Owsianowsky; A Rehbein; F W Busch
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 3.  Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?

Authors:  B M Vose
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

4.  Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells.

Authors:  M Pfreundschuh; B Dörken; W Brandeis; W Hunstein; P Wernet
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.

Authors:  G Pawelec; H Schmidt; A Rehbein; F Busch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Autologous responses to human leukaemic cells in mixed leucocyte culture.

Authors:  L K Ashman; D E O'Keefe; C A Juttner; I R Toogood; M S Rice
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Proliferative and cytotoxic responses of human peripheral blood lymphocytes to autologous malignant effusions. An analysis at the clonal level.

Authors:  T E Roberts; U Shipton; M Moore
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.